^
over4years
[VIRTUAL] TRX-E-002-1 in treatment-refractory ovarian cancer - 3-month follow-up results from a phase I study dose escalation phase (AACR-II 2020)
IP administered TRX-E-002-1 as a first-in-class, dual acting, anti-cancer therapy has preliminary activity for the treatment of platinum resistant ovarian cancer for patients who have demonstrated resistance to a range of prior treatments.
P1 data • PARP Biomarker
|
CD44 (CD44 Molecule)
|
Cantrixil (TRX-E-002-1)
over4years
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (clinicaltrials.gov)
P1, N=28, Completed, Kazia Therapeutics Limited | Active, not recruiting --> Completed | Trial primary completion date: Dec 2019 --> Mar 2020
Clinical • Trial completion • Trial primary completion date
|
BRCA (Breast cancer early onset)
|
Cantrixil (TRX-E-002-1)